Related Experiment Videos
The tamoxifen controversy
1Methodist Hospital San Antonio, TX, USA.
Oncology Nursing Forum
|June 1, 1996
Summary
Tamoxifen reduces contralateral breast cancer by 40%, but increases endometrial cancer risk. Women taking tamoxifen should be educated on recognizing uterine abnormalities and reporting them promptly.
Area of Science:
- Oncology
- Pharmacology
- Gynecology
Background:
- Tamoxifen is a widely used medication for breast cancer treatment and prevention.
- Controversies surround tamoxifen's use, including its effects on the uterus and common side effects.
- The Breast Cancer Prevention Trial highlighted tamoxifen's benefits and risks.
Purpose of the Study:
- To review controversies surrounding tamoxifen.
- To examine the increased incidence of benign uterine conditions and endometrial cancer.
- To discuss tamoxifen's side effects and screening recommendations for endometrial cancer.
Main Methods:
- A comprehensive review of published literature.
- Inclusion of articles, bulletins, books, and monographs.
Main Results:
- Tamoxifen acts as an antiestrogen in breast tissue but has estrogenic effects on bones, cardiovascular system, endometrium, and liver.
- Women with breast cancer on tamoxifen have a 2-3 times higher risk of endometrial cancer.
- This risk poses a significant physical and psychological impact on patients.
Conclusions:
- The benefit of a 40% reduction in contralateral breast cancer outweighs the risk of endometrial cancer.
- Further research should investigate quality of life and emotional responses to cancer prevention.
- Nurses play a crucial role in educating patients about recognizing and reporting endometrial cancer symptoms.